Anticompetitive practices within the pharmaceutical industry, coupled with outdated patent laws that inhibit more affordable biosimilars and generics, have resulted in skyrocketing drug costs for all Americans, especially seniors and those with chronic conditions. ACHP advocates for sensible policies such as price transparency to rein in sky-high costs so that patients can afford the medications they need. ACHP’s Fix List targets six key areas: lowering prices, sustainable spending, innovative financing, patent reform, advertising restrictions and supply chain transparency.
